We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+3.85%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.11B
AUM Growth
+$28.3M
Cap. Flow
+$26.6M
Cap. Flow %
0.86%
Top 10 Hldgs %
33.83%
Holding
206
New
17
Increased
43
Reduced
39
Closed
34

Top Buys

Rank Stock Value
1
RLYB icon
Rallybio
RLYB
+$33.8M
2
IDXX icon
Idexx Laboratories
IDXX
+$30.1M
3
GH icon
Guardant Health
GH
+$27.2M
4
AMGN icon
Amgen
AMGN
+$25.7M
5
AZN icon
AstraZeneca
AZN
+$21.2M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$35.4M
2
RMD icon
ResMed
RMD
+$33.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.9M
4
DXCM icon
DexCom
DXCM
+$20.1M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$12.2M

Sector Composition

Rank Sector Weight
1 Healthcare 96.51%
2 Real Estate 2.72%
3 Industrials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
1
Moderna
MRNA
$23B
$177M 5.69%
459,456
-6,321
-1% -$2.33M
AMGN icon
2
Amgen
AMGN
$209B
$122M 3.94%
574,918
+111,513
+24% +$25.7M
UNH icon
3
UnitedHealth
UNH
$383B
$120M 3.85%
306,129
-9,419
-3% -$3.9M
GILD icon
4
Gilead Sciences
GILD
$163B
$119M 3.84%
1,708,065
+73,280
+4% +$5.15M
HZNP
5
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$99.7M 3.21%
910,340
-26,000
-3% -$2.7M
REGN icon
6
Regeneron Pharmaceuticals
REGN
$77.4B
$89.6M 2.88%
148,015
+9,883
+7% +$6.14M
TMO icon
7
Thermo Fisher Scientific
TMO
$214B
$83.5M 2.69%
146,116
+5,986
+4% +$3.29M
JNJ icon
8
Johnson & Johnson
JNJ
$617B
$83.4M 2.69%
516,652
– –
ILMN icon
9
Illumina
ILMN
$31B
$78.7M 2.53%
199,394
-8,066
-4% -$3.71M
ABT icon
10
Abbott
ABT
$183B
$77.6M 2.5%
657,038
-93,959
-13% -$11.5M
MDT icon
11
Medtronic
MDT
$110B
$75.3M 2.42%
600,722
+54,000
+10% +$6.99M
BIIB icon
12
Biogen
BIIB
$30.7B
$66.2M 2.13%
233,853
+24,729
+12% +$8.1M
LLY icon
13
Eli Lilly
LLY
$1.03T
$63.6M 2.05%
275,432
+18,871
+7% +$4.66M
MRK icon
14
Merck
MRK
$321B
$61.3M 1.97%
816,305
+274,602
+51% +$20.9M
ABBV icon
15
AbbVie
ABBV
$455B
$56.5M 1.82%
524,213
-93,090
-15% -$10.6M
IDXX icon
16
Idexx Laboratories
IDXX
$44.1B
$49.5M 1.6%
79,663
+44,849
+129% +$30.1M
VRTX icon
17
Vertex Pharmaceuticals
VRTX
$122B
$49.5M 1.59%
273,046
-122,242
-31% -$23.9M
AZN icon
18
AstraZeneca
AZN
$266B
$48.8M 1.57%
406,464
+182,315
+81% +$21.2M
GH icon
19
Guardant Health
GH
$20.2B
$48.5M 1.56%
387,984
+229,257
+144% +$27.2M
DHR icon
20
Danaher
DHR
$138B
$45.3M 1.46%
167,714
-19,805
-11% -$5.39M
CI icon
21
Cigna
CI
$76.1B
$44.4M 1.43%
221,740
+10,722
+5% +$2.33M
SYK icon
22
Stryker
SYK
$133B
$39.7M 1.28%
150,500
– –
SRPT icon
23
Sarepta Therapeutics
SRPT
$1.64B
$39.4M 1.27%
426,514
+233,290
+121% +$18M
RLYB icon
24
Rallybio
RLYB
$85.3M
$37.6M 1.21%
+288,584
New +$33.8M
BMY icon
25
Bristol-Myers Squibb
BMY
$132B
$36.2M 1.17%
612,236
-43,737
-7% -$2.88M
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Tekla Capital Management held 206 positions worth $3.11B, up 0.92% from $3.08B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Tekla Capital Management's Q3 2021 filing shows 17 new, 43 increased, 39 reduced and 34 closed positions. Its largest new stake was Rallybio: 288,584 shares worth $37.6M. The largest sale was Elevance Health, an estimated $35.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q3 2021 buy was Rallybio: 288,584 shares worth $37.6M.
  • Tekla Capital Management added most to Idexx Laboratories in Q3 2021, an estimated $30.1M increase.
  • Tekla Capital Management's biggest Q3 2021 reduction was Elevance Health, cutting an estimated $35.4M.
  • Tekla Capital Management fully exited Iovance Biotherapeutics in Q3 2021, selling an estimated $12.2M.
  • Tekla Capital Management's ten largest holdings make up 34% of its $3.11B portfolio in Q3 2021.
  • Tekla Capital Management opened 17 new positions and closed 34 in Q3 2021.
  • Tekla Capital Management's portfolio value rose 0.92% quarter-over-quarter to $3.11B.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.